Effects of increased iron intake during the neonatal period on the brain of adult AβPP/PS1 transgenic mice

Journal of Alzheimer's Disease

Volumn 19, Issue 3, 2010, Pages 1069-1080

  Fernandez, Liana Lisboa ^a,b,c   Carmona, Marga ^c   Portero Otin, Manuel ^d   Naudi, Alba ^d   Pamplona, Reinald ^d   Schröder, Nadja ^a   Ferrer, Isidro ^c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Federal Foundation School of Medical Sciences   (Brazil)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Alzheimer's disease; A PP PS1 transgenic mice; Docosahexaenoic acid; Docosapentaenoic acid; GFAP; Iron; Neurodegeneration; Peroxidizability index; Protein oxidation

Indexed keywords

6 N CARBOXYMETHYLLYSINE; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; DIAMINO ACID; FATTY ACID; GLUTAMIC ACID DERIVATIVE; GLUTAMIC SEMIALDEHYDE; GREEN FLUORESCENT PROTEIN; N EPSILON CARBOXYETHYLLYSINE; N EPSILON MALONDIALDEHYDELYSINE; PRESENILIN 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENVIRONMENTAL FACTOR; GEL ELECTROPHORESIS; GENETIC RISK; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRON INTAKE; IRON THERAPY; LIPID COMPOSITION; MOUSE; NEUROPATHOLOGY; NEWBORN PERIOD; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 77149134320     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1304     Document Type: Article

References (43)

1. Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11, 111-128.
2. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegenaration. Nat Med 10 (Suppl), S2-S9.
3. Selkoe DJ (2004) Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6, 1054-1061.
4. Blennow K, De Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
5. Bertram L, Tanzi RE (2005) The genetic epidemiology of neurodegenerative disease. J Clin Invest 115, 1449-1457.
6. Fernandez LL, Scheibe RM (2005) Is MTHFR polymorphism a risk factor for Alzheimer's disease like APOE? Arq Neuropsiquiatr 63, 1-6.
7. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked Presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
8. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2, 864-870.
9. McGowan E, Sanders S, Iwatsubo T, Takeuchi A, Saido T, Zehr C, Yu X, Uljon S, Wang R, Mann D, Dickson D, Duff K (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6, 231-244.
10. Manaye KF, Wang PC, O'Neil JN, Huang SY, Xu T, Lei DL (2007) Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry. Age 29, 87-96.
11. Perez M, Moran MA, Ferrer I,Avila J, Gomez-Ramos P (2008) Phosphorylated tau in neuritic plaques of APPsw/tauvlw transgenic mice and Alzheimer disease. Acta Neuropathol 116, 409-418.
12. Rodriguez JJ, Olabarria M, Cchvatal A, Verkhratsky A (2009) Astroglia in dementia and Alzheimer's disease. Cell Death Diff 16, 378-385.
13. Knafo S, Alonso-Manclares L, Gonzalez-Soriano J, Merino-Serais P, Fernaud-Espinosa I, Ferrer I, DeFelipe J (2009) Widespread changes in dendritic spines in a model of Alzheimer disease. Cereb Cortex 19, 586-592.
14. Egaña JT, Zambrano C, Nuñez MT, Gonzalez-Billault C, Maccioni RB (2003) Iron-induced oxidative stress modifies tau phosphorylation patterns in hippocampal cell cultures. Biometals 16, 215-223.
15. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI (2004) Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization. J Biol Inorg Chem 9, 954-960.
16. Riederer PF (2004) View on neurodegeneration as a basis for neuroprotective strategies. Med Sci Monit 10, RA287-290.
17. Lee DW, Andersen JK, Kaur D (2006) Iron dysregulation and neurodegeneration: the molecular connection. Mol Interven 6, 89-97.
18. Fernandez LL, Fornari LHT, Barbosa MV, Schroder N (2007) Iron and neurodegeneration. Scientia Medica 17, 218-224.
19. Molina-Holgado F, Hider RC, Gaeta A, Williams R, Francis P (2007) Metal iron and neurodegeneration. Biometals 20, 639-654.
20. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X (2007) Iron: The redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 32, 1640-1645.
21. Quintana C, Bellefqih S, Laval JY, Guerquin-Kern JL,Wu TD, Avila J, Ferrer I, Arranz R, Patiño C (2006) Study of the localization of iron, ferritin, and hemossiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 153, 42-54.
22. Gaasch JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ (2007) Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem Res 32, 1196-1208.
23. Falangola MF, Lee SP, Nixon RA, Duff K, Helpem JA (2005) Histological co-localization of iron in Aβ plaques of PS/APP transgenic mice. Neurochem Res 30, 201-205.
24. Fredriksson A, Schröder N, Eriksson P, Izquierdo I, Archer T (1999) Neonatal iron exposure induces neurobehavioral dysfunction in adult mice. Toxicol Appl Pharmacol 159, 25-30.
25. Fredriksson A, Schröder n, Eriksson P, Izquierdo I, Archer T (2000) Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical post natal period. Dev Brain Res 119, 65-74.
26. Schröder N, Fredriksson A, Vianna MRM, Roesler R, Izquierdo I, Archer T (2001) Memory deficits in adult rats following post natal iron administration. Behav Brain Res 124, 77-85.
27. de Lima MN, Presti-Torres J, Garcia VA, Guimarães MR, Scalco FS, Roesler R, Schröder N (2008) Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats. Neuropharmacology 55, 788-792.
28. de Lima MNN, Presti-Torres J, Caldana F, Grazziotin MM, Scalco FS, Guimarães MR (2007) Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats. Eur J Pharmacol 570, 111-114.
29. de Lima MN, Polydoro M, Laranja DC, Bonatto F, Bromberg E, Moreira JC, Dal-Pizzol F, Schröder N (2005) Recognition memory impairment and brain oxidative stress by postnatal iron administration. Eur J Neurosci 21, 2521-2528.
30. de Lima MN, Laranja DC, Caldana F, Grazziotin MM, Garcia VA, Dal-Pizzol F, Bromberg E, Schröder N (2005) Selegiline protects against recognition memory impairments induced by neonatal iron treatment. Exp Neurol 196, 177-183.
31. Pamplona R, Dalf́o E, Ayala V, Bellmunt MJ, Prat J, Ferrer I, Portero-Ot́in M (2005) Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280, 21522-21530.
32. Kontush A (2004) Apolipoprotein Aβ: Black sheep in a good family. Brain Pathol 14, 433-446.
33. Bishop GM, Robinson SR (2004) The Amyloid paradox: Amyloid-β-metal complexes can be neurotoxic and neuroprotective. Brain Pathol 14, 448-452.
34. Wharton SB, O'Callaghan JP, Savva GM, Nicoll JA, Matthews F, Simpson JE, Forster G, Shaw PJ, Brayne C, Ince PG; MRC Cognitive Function and Ageing Neuropathology Study Group (2009) Population variation in glial fibrillary acidic protein levels in brain ageing: relationship to Alzheimer-type pathology and dementia. Dement Geriatr Cogn Disord 27, 465-473.
35. Kokoszko A, Dabrowski J, Lewinski A, Karbownik-Lewinska M (2008) Protective effects of GH and IGF-1 against ironinduced lipid peroxidation in vivo. Exp Toxicol Pathol 60, 453-458.
36. Breusing N, Grune T (2008) Regulation of proteasomemediated protein degradation during oxidative stress and aging. Biol Chem 389, 203-209.
37. Pamplona R (2008) Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity. Biochim Biophys Acta 1777, 1249-1262.
38. Salmina AB (2009) Neuron-glia interactions as therapeutic targets in neurodegeneration. J Alzheimers Dis 16, 485-502.
39. Wu LL, Zhang L, Shao J, Qin YF, Yang RW, Zhao ZY (2008) Effect of postnatal iron deficiency on myelination and associated behaviors in rat pups. Behav Brain Res 188, 263-270.
40. Georgieff MK (2008) The role of iron in neuropdevelopment: fetal iron deficiency and the developing hippocampus. Biochem Soc Trans 36, 1267-1271.
41. Tran PV, Fretham SJ, Carlson ES, Georgieff MK (2009) Longterm reduction of hippocampal BDNF activity following fetalneonatal iron deficiency in adult rats. Pediatr Res 65, 493-498.
42. Carlson ES, Tkac I, Magid R, O'Connor MB, Andrews NC, Schallert T, Gunshin H, Georgieff MK, Petryk A (2009) Iron is essential for neuron development and memory functions in mouse hippocampus. J Nutr 139, 672-679.
43. Collard KJ (2009) Iron homeostasis in the neonate. Pediatrics 123, 1208-1216.